Study Title: Caffeine for Cognitive Function in Alzheimer's Disease
Intervention: Caffeine supplementation
Phase: Phase 3
Participants: 248
Status: Completed
Caffeine acts through adenosine receptor antagonism:
- Target: Adenosine A1 and A2A receptors
- Mechanism: Blocking adenosine receptors reduces neuronal inhibition, enhances excitability
- AD connection: Caffeine may improve memory through reduced neuroinflammation and improved synaptic plasticity
Caffeine is the most widely consumed psychoactive substance globally:
- Observational studies suggest coffee consumption is associated with reduced AD risk
- Caffeine crosses the blood-brain barrier
- A2A receptor antagonism may protect against amyloid toxicity
- Repurposing opportunity for a well-tolerated, inexpensive intervention
- Randomized, double-blind, placebo-controlled
- Caffeine supplementation vs. placebo
- Primary: Cognitive measures (ADAS-Cog, MMSE)
- Secondary: Functional measures, safety
NCT04570085
- ClinicalTrials.gov: NCT04570085